Cyclacel Pharmaceuticals (NASDAQ:BGMS) Issues Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) released its quarterly earnings data on Monday. The company reported ($2.21) EPS for the quarter, Zacks reports.

Cyclacel Pharmaceuticals Trading Down 3.7%

BGMS opened at $0.96 on Tuesday. The business’s 50-day moving average price is $1.04. Cyclacel Pharmaceuticals has a 12-month low of $0.73 and a 12-month high of $100.75. The firm has a market cap of $4.72 million, a price-to-earnings ratio of -0.01 and a beta of -0.45.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cyclacel Pharmaceuticals currently has a consensus rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.